The year 2014 was a heady one for medtech M&A, with bigger deals and more invested in them than ever before – $89.3 billion, according to Informa’s Strategic Transactions.
A lot of the 2014 M&A impetus was driven by pressures in the US to find a way around the high corporate tax rate. (See Also see "Biopharma In...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?